Genomed Spólka Akcyjna (GEN) fair value: what the stock is really worth
As of Nov 4, 2026: fair value (intrinsic value) of Genomed Spólka Akcyjna stock PLN 53.97, price PLN 39.00, upside +38.4%, quality 76 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range 16.94 PLN – 47.05 PLN · fair‑value band 32.04 PLN – 68.69 PLN · the 39.00 PLN price screens below the 53.97 PLN fair value. As of Nov 4, 2026.
Follow Genomed Spólka Akcyjna in your weekly email
Every Wednesday you see whether Genomed Spólka Akcyjna is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Genomed Spólka Akcyjna provides DNA and RNA sequencing and analysis and diagnostics services for congenital diseases in Poland. It develops molecular diagnostics based on DNA sequencing for the application of prophylactics and treatment, such as replacement or gene therapy.
Show moreShow less
The company's diagnostic services include DNA isolation, PCR amplification of chosen DNA regions, comparison of the sequences, and interpretation of the results by diagnosticians.
It also provides various types of DNA sequence analysis, including polymorphism analysis or sequencing of phage genetic material or bacteria genomes; and next-generation sequencing and genetic counseling services.
In addition, the company offers DNA oligonucleotides synthesis, RNA oligonucleotides and peptide synthesis, various nucleotide modifications, and the 4LAB automated pipetting workstation, as well as laboratory equipment through e-store.
It serves scientific institutes, universities, hospitals, and biotechnological and pharmaceutical companies, as well as healthcare networks and individual customers. The company was founded in 2007 and is headquartered in Warsaw, Poland.
Stock analysis
Genomed Spólka Akcyjna (GEN) currently trades at 39.00 PLN, while our model-based Fair Value estimate is 53.97 PLN, implying the stock looks roughly 28% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 53.97 PLN per share, and 18 of the 24 models we run sit above the 39.00 PLN price.
Bear case: the Asset-Based group reads lowest at 6.96 PLN, and 6 of the 24 models stay below the price. Data coverage for this calculation is high.
Scenario range: 32.04 PLN (bear) to 68.69 PLN (bull), the price of 39.00 PLN sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 76/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Genomed Spólka Akcyjna reported revenue of 29.1M PLN in FY2025 versus 20.5M PLN in FY2022, a compound +12.5%/yr. Reported net income was 3.4M PLN in FY2025, compounding +115.9%/yr from FY2022. FY2022 was a trough year, so the rate overstates the trend.
Key figures
Market cap 49.1M PLN (≈ $12.6M) Micro · P/E ratio 14.9 · P/S ratio 1.60 · EPS (TTM) 2.62 PLN · Dividend yield 3.8% · Net margin 11.4% · Return on equity 30.0% · Return on assets (EBIT) 12.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 71 out of 100 (low confidence).
What moves the price
The share trades about 4% below its 52-week high and 130% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at 38%, GEN screens cheaper than that median.
Fair Value models
Bear32.04 PLNFair Value 53.97 PLNBull68.69 PLN
Price 39.00 PLN · Upside +38.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.9482 PLN per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.92/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+26.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.5%
’22
’23
’24
’25
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
≈ +81.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+78.1%
Dividend (yield on the price)3.8%
Profit margin 2022 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.2% → 14%
⚠ Approximate: the rate leans on 2025, which sits 285% above its own trend.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+8.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Poland: IMF forecast 3.1% a year to 2030, 4.6% from 2016 to 2025) that is about +5.4% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks
Beats the industry median on 11/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score76 · Top 25%
Fair Value upside+38.4% · Top 25%
Profitability
Return on equity (12 months)30.0% · Top 25%
Return on assets20.6% · Top 25%
Net margin (12 months)11.4% · Above median
Operating margin (12 months)8.6% · Below median
Growth and dividend
Revenue growth (quarter YoY)17.5% · Above median
Dividend yield (12 months)3.8% · Top 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Genomed Spólka Akcyjna (GEN) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 53.97 PLN versus a price of 39.00 PLN, about +38% upside (undervalued).
What is the fair value of GEN?
Our model-based fair value for Genomed Spólka Akcyjna is 53.97 PLN (as of Nov 4, 2026), built from audited fundamentals. The current price: 39.00 PLN.
What is the quality score of GEN?
Genomed Spólka Akcyjna has a Quality Score of 76/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Genomed Spólka Akcyjna (GEN)?
Our model-based price target is the fair value of 53.97 PLN (as of Nov 4, 2026) from 24 valuation models. Cautious scenario 32.04 PLN, optimistic scenario 68.69 PLN. It is a calculation from audited fundamentals, not an analyst target.
What is the Genomed Spólka Akcyjna stock forecast for 2026?
Our models put fair value at 53.97 PLN, about +38% upside versus a price of 39.00 PLN (undervalued). Cautious scenario 32.04 PLN, optimistic scenario 68.69 PLN. The calculation is refreshed regularly with new filings.
What is the revenue of Genomed Spólka Akcyjna (GEN)?
Genomed Spólka Akcyjna reported trailing-twelve-month revenue of about 30.6M PLN (latest available figure, as of Nov 4, 2026).
Does Genomed Spólka Akcyjna pay a dividend?
Genomed Spólka Akcyjna currently shows a dividend yield of 3.85% relative to its recent price (as of Nov 4, 2026).
What growth is priced into Genomed Spólka Akcyjna (GEN)?
For today's price to be fair in a discounted-cash-flow model, Genomed Spólka Akcyjna would have to grow free cash flow by +8.8 % per year for five years (discount rate 9.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 3 years revenue grew +12.5 % per year. As of Nov 4, 2026.
What discount rate (WACC) does the fair value of GEN use?
Our models discount Genomed Spólka Akcyjna at 9.3 %: a base by market capitalisation (nano), damped by beta 0.01, country premium for Poland. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Genomed Spólka Akcyjna that is +8.8 % per year a year over ten years, using the same discount rate (9.3 %) and the same formula as our fair value.
How much growth has Genomed Spólka Akcyjna (GEN) delivered so far?
Over the past 3 years revenue at Genomed Spólka Akcyjna grew +12.5 % a year. The price currently implies +8.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Genomed Spólka Akcyjna (GEN) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into Genomed Spólka Akcyjna (+8.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Genomed Spólka Akcyjna (GEN)?
The free-cash-flow yield on the price is 4.30 %: that much free cash flow Genomed Spólka Akcyjna produces per unit of market value. When it exceeds the discount rate of our models (9.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Genomed Spólka Akcyjna (GEN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Genomed Spólka Akcyjna it is 53.97 PLN per share (as of Nov 4, 2026), against a price of 39.00 PLN. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Genomed Spólka Akcyjna stock overvalued or undervalued in 2026?
As of Nov 4, 2026, GEN trades below its calculated fair value: price 39.00 PLN, fair value 53.97 PLN, a gap of about +38% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GEN?
No. The price is what the market pays today (39.00 PLN); the fair value is what the company's own numbers justify (53.97 PLN). For Genomed Spólka Akcyjna the two are 14.97 PLN per share apart. That gap is exactly why we show both numbers side by side.
How much is Genomed Spólka Akcyjna worth?
The market values Genomed Spólka Akcyjna at about 49.1M PLN (market capitalisation, as of Nov 4, 2026). Per share that is 39.00 PLN; our models calculate a fair value of 53.97 PLN per share.
What do the bullish and bearish scenarios say about GEN?
Our models span a range for Genomed Spólka Akcyjna: cautious scenario 32.04 PLN, base 53.97 PLN, optimistic 68.69 PLN per share (as of Nov 4, 2026, price 39.00 PLN). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of GEN?
Genomed Spólka Akcyjna trades at a price-to-earnings ratio of 14.9 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 53.97 PLN is built from several models across several years. Other multiples: P/B 3.5, P/S 1.6, EV/EBITDA 8.5.
How solid is the balance sheet of Genomed Spólka Akcyjna (GEN)?
Balance-sheet figures for Genomed Spólka Akcyjna (as of Nov 4, 2026): return on equity 30.0%. They feed the Quality Score of 76/100, which measures business quality independently of the share price.
How far is GEN from its 52-week high?
Genomed Spólka Akcyjna trades at 39.00 PLN, about 4% below its 52-week high of 40.80 PLN and 130% above the low of 16.94 PLN (as of Nov 4, 2026). Distance from the high says nothing about value: that is what the fair value of 53.97 PLN is for.
Which stocks are comparable to Genomed Spólka Akcyjna?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Genomed Spólka Akcyjna stock attractive at the current price?
The data as of Nov 4, 2026: price 39.00 PLN, calculated fair value 53.97 PLN (+38%), Quality Score 76/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GEN calculated?
We run Genomed Spólka Akcyjna through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 53.97 PLN, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0% above its aggregate fair value. Genomed Spólka Akcyjna currently trades 28% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Genomed Spólka Akcyjna (GEN)?
The closing price on Nov 4, 2026 was 39.00 PLN. Our model-based fair value is 53.97 PLN, about +38% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Genomed Spólka Akcyjna right now?
The rarer combination: high quality (76/100) AND below fair value. That earns a closer look rather than a quick verdict. A fairly wide model range (32.04 PLN to 68.69 PLN) leaves room in how you read the outcome.
Key figures of Genomed Spólka Akcyjna
How large is the market capitalisation of Genomed Spólka Akcyjna (GEN)?
The market capitalisation of Genomed Spólka Akcyjna is 49.1M PLN (≈ $12.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Genomed Spólka Akcyjna (GEN)?
The price-to-sales ratio of Genomed Spólka Akcyjna is 1.60 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Genomed Spólka Akcyjna (GEN)?
Earnings per share at Genomed Spólka Akcyjna are 2.62 PLN (price ÷ EPS = P/E 14.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Genomed Spólka Akcyjna (GEN)?
The dividend yield of Genomed Spólka Akcyjna is 3.8% (payout 57.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Genomed Spólka Akcyjna (GEN)?
The net margin of Genomed Spólka Akcyjna is 11.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Genomed Spólka Akcyjna (GEN)?
The return on equity (ROE) of Genomed Spólka Akcyjna is 30.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Genomed Spólka Akcyjna (GEN)?
On an EBIT basis the return on assets of Genomed Spólka Akcyjna is 12.0% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Genomed Spólka Akcyjna (GEN)?
The operating margin of Genomed Spólka Akcyjna is 8.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Genomed Spólka Akcyjna (GEN)?
Revenue at Genomed Spólka Akcyjna is growing +17.5% versus a year earlier (3y avg +12.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
Free · no account needed
Watch Genomed Spólka Akcyjna in the live analysis
One click puts Genomed Spólka Akcyjna on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
